News
01-07-2014, 06:00 AM
Celgene International SÃ*rl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.
More... (http://www.news-medical.net/news/20140107/EC-grants-approval-for-ABRAXANE-in-combination-with-gemcitabine-for-metastatic-pancreatic-cancer.aspx)
More... (http://www.news-medical.net/news/20140107/EC-grants-approval-for-ABRAXANE-in-combination-with-gemcitabine-for-metastatic-pancreatic-cancer.aspx)